A Comparison of Tumor-Associated and Non-Tumor-Associated Gastric Microbiota in Gastric Cancer PatientsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
The gastric mucosal microbiome was compared between gastric cancer (GC) patients and superficial gastritis (SG) patients. Paired tumor and paracancerous samples came from 18 GC patients treated surgically, and comparison samples came from 32 SG patients treated by gastroscopy.
How was it studied?
Gastric mucosal samples underwent 16S rRNA sequencing. Differential taxa were identified using linear discriminant analysis effect size (LEfSe), and PICRUSt was used to predict functional pathways from the community profiles.
What did they find?
GC patients had a distinct microbiota profile from SG patients, evident in both tumor and paracancerous tissue. Six bacterial genera were enriched and eighteen were depleted in GC tissue relative to SG tissue. A resulting microbial dysbiosis index (MDI) was higher in GC patients, correlated negatively with Shannon diversity, correlated positively with Helicobacter abundance, and discriminated GC from SG samples. Functional analysis suggested GC patients were more likely to harbor a nitrosating microbial community.
Why it matters
The findings suggest gastric dysbiosis, largely driven by shifts in Helicobacter abundance, distinguishes gastric cancer from superficial gastritis. The MDI offers a potential microbiome-based marker for discriminating between these conditions.